OCS

Oculis Holding AG

12.54 USD
+0.35 (+2.87%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Oculis Holding AG stock is down -6.42% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 February’s closed higher than January.

About Oculis Holding AG

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.